Replies to post #274596 on Avid Bioservices Inc (CDMO)

[biopharm]

It certainly will be a moment many have been waiting for, to find out what type of initial news Peregrine brings Monday... and for the #1 killer NSCLC and just after Peregrine announced an initial 109% MOS improvement and settled for 60% MOS improvement...

to come back now with a phase III and announce a 100%+ MOS improvement will certainly make some noise, especially having a patent filed for the biomarkers found (likely in Phase II and other trials...and then all built into Sunrise Phase III)

The "other types of analysis" should tell us all that Mondays news, no matter how big... is not the end of the data accumulation and they (Peregrine) will probably be saving extra news for another time to be announced

from the 9-8-16/CC re: SUNRISE - “some pts are continuing to receive bavituximab, over a year now. At ESMO, we will be presenting...”

....because it's a great opportunity and it’s not often you get a set of data this big in which we had already prospectively built in a lot of biomarker and other types of analysis into the study.
..
..

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125599137